

## SCYNEXIS Introduces Application for Mobile Access to HEOS Information System

RESEARCH TRIANGLE PARK, NC -- (MARKET WIRE) -- 11/10/10 -- Drug discovery and development company SCYNEXIS announced today the development of an iPhone application to allow mobile access to the company's HEOS® web-based SaaS drug research information management software.

The new HEOS Mobile App provides pharmaceutical researchers instantaneous access to the HEOS information on iPhone mobile devices. HEOS Mobile is available through the Apple App Store in the U.S. and Canada. The company is currently applying for release outside of North America.

HEOS is used by pharmaceutical and biotechnology companies around the world. It has also become the global standard for web-based knowledge sharing for drug discovery activities for so-called neglected diseases. It supports the tropical disease research databases and the partner networks of more than 70 organizations worldwide by capturing, harmonizing and consolidating information.

"We're extremely excited to be able to provide our customers with HEOS information securely and instantaneously through the simple touch of a mobile device, making this important research information even more meaningful in today's highly-connected world," said Dr. Yves Ribeill, president and chief executive officer of SCYNEXIS. "The HEOS® system is already earning a great reputation as an information management tool and this will help make its remarkable abilities even more impactful."

The HEOS mobile iPhone app provides researchers access to the full range of HEOS information management that includes chemical, biological, ADMET, physio-chemical properties and PK information.

## About SCYNEXIS

SCYNEXIS delivers integrated, efficient and innovative drug discovery and development solutions to our global health and pharmaceutical partners. Our record of success is exemplified by the delivery of eleven pre-clinical drug candidates over the last five years. SCYNEXIS' teams are tailored to be especially effective in moving customer projects from concept to clinic, utilizing powerful proprietary technologies such as the HEOS® SaaS Software Platform for comprehensive drug discovery information management and the MEDCHEM-FACTORY® High-Throughput Synthesis and Purification Platform.

Our fully-integrated contract research solutions include medicinal chemistry, advanced biological screening, in vitro pharmacology and ADMET, DMPK, bioanalytical and analytical chemistry, process chemistry, and cGMP manufacturing.

Our process chemistry department has achieved positive outcomes with general inspection and pre-approval inspection (PAI) by the FDA in support of customer NDA.

Founded in 2000, SCYNEXIS is located in Research Triangle Park, N.C. SCYNEXIS is registered with both the FDA and DEA. Please visit our website at <a href="https://www.scynexis.com">www.scynexis.com</a>.

®HEOS and MEDCHEM-FACTORY are registered trademarks of SCYNEXIS, Inc.

```
<b>For further information, please contact:
</b>
<b>SCYNEXIS, Inc.
</b>Terry Marquardt
Executive Director
Market Development & Communications
terry.marquardt@scynexis.com
Tel: +1-919-544-8603
<b>SCYNEXIS Media Contacts:
</b>Rick Rountree
Rick Rountree Communications, Inc.
rick@rickrountree.com
Tel. +1 919-878-1144
Sarah Cavanaugh
MacDougall Biomedical Communications
scavanaugh@macbiocom.com
Tel. +1 781-235-3060
```